A History of Cooper Companies (The) MTA
The Story of an S&P 500 Company

About this book:

The Cooper Companies began in 1959 when Parker Montgomery founded Cooper Tinsley Laboratories, focusing on ophthalmic instruments and the nascent contact lens market. The early decades were defined by strategic pivoting: the 1970s saw an aggressive, often unwieldy acquisition spree and formal entry into soft contact lenses, while the 1980s and 1990s brought a critical reorganization into specialized units and a decisive divestiture of non-core assets to focus exclusively on vision care through CooperVision. This specialization fueled a period of intense innovation in the 2000s, where CooperVision led the market transition to silicone hydrogel materials and daily disposable lenses, expanding its global manufacturing and distribution footprint to become a dominant force in vision correction.

In the early 2010s, the company executed a calculated re-diversification by aggressively building CooperSurgical into a comprehensive women’s health leader. Through strategic acquisitions—most notably Origio in 2012—CooperSurgical assembled a broad portfolio spanning fertility solutions (IVF media, genetic testing), surgical instruments, and diagnostic products. This dual-pillar strategy (CooperVision and CooperSurgical) de-risked the business, created two distinct high-growth engines, and demonstrated the firm’s mature capability for integrating complex acquisitions while maintaining rigorous regulatory compliance and manufacturing excellence across diverse medical device categories.

Underpinning this commercial evolution was a consistent commitment to research and development, driving breakthroughs such as myopia management contact lenses (MiSight) and AI-enhanced fertility diagnostics. The company cultivated a culture of scientific rigor, employee empowerment, and ethical responsibility, extending into sustainability initiatives like contact lens recycling programs and community-focused philanthropy in vision and women’s health access. These efforts, combined with disciplined financial management and consistent shareholder returns, culminated in inclusion in the S&P 500, validating a legacy built on adaptability, specialized innovation, and a patient-centric mission.

Today, Cooper Companies stands as a resilient S&P 500 enterprise defined by its dual leadership in vision care and women’s health. Its trajectory—from a small ophthalmic venture to a global medical device powerhouse—reflects a enduring formula of strategic focus, technological leadership, and operational discipline. As it advances into an era of smart lenses, personalized reproductive medicine, and AI-driven healthcare, the company continues to leverage its integrated R&D, manufacturing, and commercial capabilities to address critical unmet needs, ensuring its legacy of innovation and growth persists.

What You'll Find Inside:

• The evolution of Cooper Companies from a 1959 ophthalmic startup to a dual-focused S&P 500 leader in vision care (CooperVision) and women's health (CooperSurgical).
• Strategic discipline demonstrated through the 1990s divestiture of non-core assets to specialize in contact lenses, followed by the 2010s re-diversification into women's health via targeted acquisitions like Origio.
• Pioneering innovation in contact lenses, including the commercialization of daily disposables, silicone hydrogel materials, and the first FDA-approved myopia management lens (MiSight 1 day).
• Growth driven by a calculated mergers and acquisitions strategy that acquired key technologies, manufacturing capabilities, and global market access while successfully integrating diverse corporate cultures.
• Resilience built on manufacturing excellence, regulatory expertise, a mission-driven corporate culture, and a commitment to sustainability and corporate responsibility across global operations.

Who's It For:

This book is ideal for business leaders, entrepreneurs, and investors seeking a case study in strategic corporate evolution, specialization, and successful M&A integration. Healthcare professionals and medical device industry executives will value the deep dive into innovation cycles for contact lenses and women's health surgical products. Students of corporate history and strategy will appreciate the detailed narrative of navigating regulatory landscapes, competitive pressures, and financial milestones to achieve S&P 500 status.